Advertisement
RDY vs TAK
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RDY is a StrongBuy and TAK is a Buy.
RDY in +4.53% Uptrend, growing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where RDY advanced for three days, in 156 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on RDY as a result. In 40 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 48%.
The Moving Average Convergence Divergence (MACD) for RDY just turned positive on October 09, 2026. Looking at past instances where RDY's MACD turned positive, the stock continued to rise in 23 of 48 cases over the following month. The odds of a continued upward trend are 48%.
The Aroon Indicator entered an Uptrend today. In 87 of 243 cases where RDY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 36%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 16 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RDY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
RDY broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. RDY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.032) is normal, around the industry mean (7.659). P/E Ratio (0.371) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (1.666) is also within normal values, averaging (2.202). Dividend Yield (0.020) settles around the average of (0.062) among similar stocks. P/S Ratio (2.817) is also within normal values, averaging (181.047).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 73 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Aroon Indicator for TAK shows an upward move is likely
TAK's Aroon Indicator triggered a bullish signal on November 04, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 283 similar instances where the Aroon Indicator showed a similar pattern. In 157 of the 283 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 55%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on TAK as a result. In 43 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 45%.
The Moving Average Convergence Divergence (MACD) for TAK just turned positive on October 14, 2026. Looking at past instances where TAK's MACD turned positive, the stock continued to rise in 21 of 43 cases over the following month. The odds of a continued upward trend are 49%.
TAK moved above its 50-day moving average on October 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where TAK advanced for three days, in 156 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TAK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
TAK broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.009) is normal, around the industry mean (7.659). P/E Ratio (-0.403) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.425) is also within normal values, averaging (2.202). Dividend Yield (0.056) settles around the average of (0.062) among similar stocks. P/S Ratio (1.968) is also within normal values, averaging (181.047).
The Tickeron Profit vs. Risk Rating rating for this company is 17 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. TAK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
RDY | TAK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 36 | 85 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 49 Fair valued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 63 | 17 | |
SMR RATING 1..100 | 73 | 91 | |
PRICE GROWTH RATING 1..100 | 40 | 37 | |
P/E GROWTH RATING 1..100 | 97 | 97 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TAK's Valuation (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for RDY (49) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew somewhat faster than RDY’s over the last 12 months.
TAK's Profit vs Risk Rating (17) in the Pharmaceuticals Major industry is somewhat better than the same rating for RDY (63) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew somewhat faster than RDY’s over the last 12 months.
RDY's SMR Rating (73) in the Pharmaceuticals Generic industry is in the same range as TAK (91) in the Pharmaceuticals Major industry. This means that RDY’s stock grew similarly to TAK’s over the last 12 months.
TAK's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as RDY (40) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew similarly to RDY’s over the last 12 months.
TAK's P/E Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as RDY (97) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew similarly to RDY’s over the last 12 months.
| RDY | TAK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 58% | 2 days ago 45% |
| Stochastic ODDS (%) | 2 days ago 51% | 2 days ago 44% |
| Momentum ODDS (%) | 2 days ago 48% | 2 days ago 45% |
| MACD ODDS (%) | 2 days ago 48% | 2 days ago 49% |
| TrendWeek ODDS (%) | 2 days ago 50% | 2 days ago 48% |
| TrendMonth ODDS (%) | 2 days ago 45% | 2 days ago 49% |
| Advances ODDS (%) | 2 days ago 49% | 21 days ago 49% |
| Declines ODDS (%) | 23 days ago 55% | 3 days ago 45% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 50% |
| Aroon ODDS (%) | 2 days ago 36% | 2 days ago 55% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RDY’s FA Score shows that 0 FA rating(s) are green while TAK’s FA Score has 2 green FA rating(s).
- RDY’s FA Score: 0 green, 5 red.
- TAK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RDY’s TA Score shows that 4 TA indicator(s) are bullish while TAK’s TA Score has 5 bullish TA indicator(s).
- RDY’s TA Score: 4 bullish, 4 bearish.
- TAK’s TA Score: 5 bullish, 4 bearish.
Price Growth
RDY (@Pharmaceuticals: Generic) experienced а +4.38% price change this week, while TAK (@Pharmaceuticals: Generic) price change was +4.52% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.07%. For the same industry, the average monthly price growth was +0.23%, and the average quarterly price growth was +23.49%.
Reported Earning Dates
RDY is expected to report earnings on Jan 22, 2027.
TAK is expected to report earnings on Jan 28, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (+3.07% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
RDY and
Correlation & Price change
A.I.dvisor tells us that RDY and VTRS have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and VTRS's prices will move in lockstep.
| Ticker / NAME | Correlation To RDY | 1D Price Change % | ||
|---|---|---|---|---|
| RDY | 100% | +3.29% | ||
| VTRS - RDY | 28% Poorly correlated | +1.59% | ||
| HROW - RDY | 26% Poorly correlated | +0.74% | ||
| DERM - RDY | 25% Poorly correlated | +1.94% | ||
| LFCR - RDY | 24% Poorly correlated | +0.31% | ||
| SNDL - RDY | 24% Poorly correlated | +4.44% | ||
More | ||||
TAK and
Correlation & Price change
A.I.dvisor indicates that over the last year, TAK has been loosely correlated with HLN. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if TAK jumps, then HLN could also see price increases.
| Ticker / NAME | Correlation To TAK | 1D Price Change % | ||
|---|---|---|---|---|
| TAK | 100% | +1.49% | ||
| HLN - TAK | 41% Loosely correlated | +4.41% | ||
| COLL - TAK | 29% Poorly correlated | -0.25% | ||
| PBH - TAK | 28% Poorly correlated | +7.55% | ||
| ANIK - TAK | 28% Poorly correlated | +4.88% | ||
| PRGO - TAK | 27% Poorly correlated | +0.83% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| RAY.X | 1.728067 | 0.184873 | +11.98% |
| Raydium cryptocurrency | |||
| BLZ.X | 0.008537 | 0.000229 | +2.75% |
| Bluzelle cryptocurrency | |||
| OGN.X | 0.025054 | 0.000425 | +1.72% |
| Origin Protocol cryptocurrency | |||
| AXL.X | 0.042456 | 0.000638 | +1.52% |
| Axelar cryptocurrency | |||
| ORN.X | 0.018105 | -0.006775 | -27.23% |
| Orion cryptocurrency | |||